Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 417
Filtrar
1.
ESMO Open ; 9(9): 103696, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39255538

RESUMEN

BACKGROUND: The combination of encorafenib with cetuximab has become the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) after a prior systemic therapy. This study aims to describe the efficacy and safety of encorafenib/cetuximab +/- binimetinib in patients with BRAF V600E-mutated mCRC in a real-world setting. PATIENTS AND METHODS: This retrospective study included patients with BRAF V600E-mutated mCRC who received this combination from January 2020 to June 2022 in 30 centers. RESULTS: A total of 201 patients were included, with 55% of women, a median age of 62 years, and an Eastern Cooperative Oncology Group performance status (ECOG-PS) >1 in 20% of cases. The main tumor characteristics were 60% of right-sided primary tumor, 11% of microsatellite instability/mismatch repair deficient phenotype, and liver and peritoneum being the two main metastatic sites (57% and 51%). Encorafenib/cetuximab +/- binimetinib was prescribed in the first, second, third, and beyond third line in 4%, 56%, 29%, and 11%, respectively, of cases, with the encorafenib/cetuximab/binimetinib combination for 21 patients (10%). With encorafenib/cetuximab treatment, 21% of patients experienced grade ≥3 adverse events (AEs), with each type of grade ≥3 AE observed in <5% of patients. The objective response rate was 32.2% and the disease control rate (DCR) was 71.2%. The median progression-free survival (PFS) was 4.5 months [95% confidence interval (CI) 3.9-5.4 months] and the median overall survival (OS) was 9.2 months (95% CI 7.8-10.8 months). In multivariable analysis, factors associated with a shorter PFS were synchronous metastases [hazard ratio (HR) 1.66, P = 0.04] and ECOG-PS >1 (HR 1.88, P = 0.007), and those associated with a shorter OS were the same factors (HR 1.71, P = 0.03 and HR 2.36, P < 0.001, respectively) in addition to treatment beyond the second line (HR 1.74, P = 0.003) and high carcinoembryonic antigen level (HR 1.72, P = 0.003). CONCLUSION: This real-world study showed that in patients with BRAF V600E-mutated mCRC treated with encorafenib/cetuximab +/- binimetinib, efficacy and safety data confirm those reported in the BEACON registration trial. The main poor prognostic factors for this treatment are synchronous metastases and ECOG-PS >1.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica , Bencimidazoles , Carbamatos , Cetuximab , Neoplasias Colorrectales , Proteínas Proto-Oncogénicas B-raf , Sulfonamidas , Humanos , Carbamatos/uso terapéutico , Carbamatos/efectos adversos , Carbamatos/administración & dosificación , Femenino , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/genética , Neoplasias Colorrectales/patología , Masculino , Persona de Mediana Edad , Proteínas Proto-Oncogénicas B-raf/genética , Estudios Retrospectivos , Cetuximab/uso terapéutico , Cetuximab/administración & dosificación , Cetuximab/farmacología , Cetuximab/efectos adversos , Sulfonamidas/uso terapéutico , Sulfonamidas/administración & dosificación , Sulfonamidas/efectos adversos , Sulfonamidas/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bencimidazoles/uso terapéutico , Bencimidazoles/administración & dosificación , Anciano , Mutación , Adulto , Anciano de 80 o más Años , Metástasis de la Neoplasia , Resultado del Tratamiento
2.
Sci Rep ; 14(1): 22207, 2024 09 27.
Artículo en Inglés | MEDLINE | ID: mdl-39333563

RESUMEN

The cultivation of grapevines has spanned millennia, leading to thousands of varieties through exchanges, mutations, and crosses between genotypes, as well probably as gene flow from wild populations. These varieties are typically categorized by regional origin and primary use, either for wine production or fruit consumption. France, within the Western European group, hosts many of the world's renowned wine grape varieties. However, the historical development of cultivated grapevines in France and in the world remains poorly understood. This study applies morphometry on 19,377 charred and waterlogged archaeological grape pips to investigate the evolutionary history of grapevine in France over the last 10,000 years. The study compares seed outlines and lengths, corrected for taphonomic distortions, with a reference collection of 80 wild and 466 modern domestic grapevine accessions. Findings reveal a shift from wild grapevine exploitation to the expansion of domestic varieties around 600-500 BCE, coinciding with Mediterranean cultural influences and the introduction of eastern grape types. The identification of the East-Table group, a group of varieties of eastern origin for fruit consumption, indicates that grapes were also grown for food, especially in Mediterranean regions and near urban areas, alongside wine production. Early French viticulture featured a notable presence of Western European wine-type grapevines. The abundance of pips with wild-like morphology suggests early cultivation involved plants at an initial domestication stage and gene flow between introduced and wild grapevines. As viticulture spread northward, wild and Eastern morphotypes declined, leading to the dominance of Western European wine types in inner France during the Middle Ages.


Asunto(s)
Semillas , Vitis , Vitis/genética , Vitis/anatomía & histología , Francia , Semillas/genética , Semillas/anatomía & histología , Vino , Evolución Biológica , Flujo Génico
5.
Cancers (Basel) ; 15(9)2023 May 02.
Artículo en Inglés | MEDLINE | ID: mdl-37174056

RESUMEN

BACKGROUND: High-risk HPV infection is responsible for >99% of cervix cancers (CC). In persistent infections that lead to cancer, the tumour breaches the basement membrane, releasing HPV-DNA into the bloodstream (cHPV-DNA). A next-generation sequencing assay (NGS) for detection of plasma HPV circulating DNA (cHPV-DNA) has demonstrated high sensitivity and specificity in patients with locally advanced cervix cancers. We hypothesised that cHPV-DNA is detectable in early invasive cervical cancers but not in pre-invasive lesions (CIN). METHODS: Blood samples were collected from patients with CIN (n = 52) and FIGO stage 1A-1B CC (n = 12) prior to treatment and at follow-up. DNA extraction from plasma, followed by NGS, was used for the detection of cHPV-DNA. RESULTS: None of the patients with pre-invasive lesions were positive for CHPV-DNA. In invasive tumours, plasma from one patient (10%) reached the threshold of positivity for cHPV-DNA in plasma. CONCLUSION: Low detection of cHPV-DNA in early CC may be explained by small tumour size, poorer access to lymphatics and circulation, and therefore little shedding of cHPV-DNA in plasma at detectable levels. The detection rate of cHPV-DNA in patients with early invasive cervix cancer using even the most sensitive of currently available technologies lacks adequate sensitivity for clinical utility.

6.
ESMO Open ; 8(3): 101198, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37119788

RESUMEN

BACKGROUND: Metastatic colorectal cancer (mCRC) patients tend to have modest benefits from molecularly driven therapeutics. Patient-derived tumor organoids (PDTOs) represent an unmatched model to elucidate tumor resistance to therapy, due to their high capacity to resemble tumor characteristics. MATERIALS AND METHODS: We used viable tumor tissue from two cohorts of patients with mCRC, naïve or refractory to treatment, respectively, for generating PDTOs. The derived models were subjected to a 6-day drug screening assay (DSA) with a comprehensive pipeline of chemotherapy and targeted drugs against almost all the actionable mCRC molecular drivers. For the second cohort DSA data were matched with those from PDTO genotyping. RESULTS: A total of 40 PDTOs included in the two cohorts were derived from mCRC primary tumors or metastases. The first cohort included 31 PDTOs derived from patients treated in front line. For this cohort, DSA results were matched with patient responses. Moreover, RAS/BRAF mutational status was matched with DSA cetuximab response. Ten out of 12 (83.3%) RAS wild-type PDTOs responded to cetuximab, while all the mutant PDTOs, 8 out of 8 (100%), were resistant. For the second cohort (chemorefractory patients), we used part of tumor tissue for genotyping. Four out of nine DSA/genotyping data resulted applicable in the clinic. Two RAS-mutant mCRC patients have been treated with FOLFOX-bevacizumab and mitomycin-capecitabine in third line, respectively, based on DSA results, obtaining disease control. One patient was treated with nivolumab-second mitochondrial-derived activator of caspases mimetic (phase I trial) due to high tumor mutational burden at genotyping, experiencing stable disease. In one case, the presence of BRCA2 mutation correlated with DSA sensitivity to olaparib; however, the patient could not receive the therapy. CONCLUSIONS: Using CRC as a model, we have designed and validated a clinically applicable methodology to potentially inform clinical decisions with functional data. Undoubtedly, further larger analyses are needed to improve methodology success rates and propose suitable treatment strategies for mCRC patients.


Asunto(s)
Neoplasias del Colon , Neoplasias Colorrectales , Humanos , Cetuximab/efectos adversos , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/genética , Neoplasias Colorrectales/patología , Mutación
7.
ESMO Open ; 8(2): 101204, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-37018873

RESUMEN

Historically women were frequently excluded from clinical trials and drug usage to protect unborn babies from potential harm. As a consequence, the impact of sex and gender on both tumour biology and clinical outcomes has been largely underestimated. Although interrelated and often used interchangeably, sex and gender are not equivalent concepts. Sex is a biological attribute that defines species according to their chromosomal makeup and reproductive organ, while gender refers to a chosen sexual identity. Sex dimorphisms are rarely taken into account, in either preclinical or clinical research, with inadequate analysis of differences in outcomes according to sex or gender still widespread, reflecting a gap in our knowledge for a large proportion of the target population. Underestimation of sex-based differences in study design and analyses has invariably led to 'one-drug' treatment regimens for both males and females. For patients with colorectal cancer (CRC), sex also has an impact on the disease incidence, clinicopathological features, therapeutic outcomes, and tolerability to anticancer treatments. Although the global incidence of CRC is higher in male subjects, the proportion of patients presenting right-sided tumours and BRAF mutations is higher among females. Concerning sex-related differences in treatment efficacy and toxicity, drug dosage does not take into account sex-specific differences in pharmacokinetics. Toxicity associated with fluoropyrimidines, targeted therapies, and immunotherapies has been reported to be more extensive for females with CRC than for males, although evidence about differences in efficacy is more controversial. This article aims to provide an overview of the research achieved so far into sex and gender differences in cancer and summarize the growing body of literature illustrating the sex and gender perspective in CRC and their impact in relation to tumour biology and treatment efficacy and toxicity. We propose endorsing research on how biological sex and gender influence CRC as an added value for precision oncology.


Asunto(s)
Neoplasias Colorrectales , Lactante , Humanos , Masculino , Femenino , Neoplasias Colorrectales/epidemiología , Neoplasias Colorrectales/genética , Neoplasias Colorrectales/terapia , Medicina de Precisión , Resultado del Tratamiento , Factores Sexuales , Oncología Médica
8.
Ann Oncol ; 34(6): 543-552, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-36921693

RESUMEN

BACKGROUND: Combination of a BRAF inhibitor (BRAFi) and an anti-epidermal growth factor receptor (EGFR), with or without a MEK inhibitor (MEKi), improves survival in BRAF-V600E-mutant metastatic colorectal cancer (mCRC) over standard chemotherapy. However, responses are heterogeneous and there are no available biomarkers to assess patient prognosis or guide doublet- or triplet-based regimens. In order to better characterize the clinical heterogeneity observed, we assessed the prognostic and predictive role of the plasmatic BRAF allele fraction (AF) for these combinations. PATIENTS AND METHODS: A prospective discovery cohort including 47 BRAF-V600E-mutant patients treated with BRAFi-anti-EGFR ± MEKi in clinical trials and real-world practice was evaluated. Results were validated in an independent multicenter cohort (n= 29). Plasmatic BRAF-V600E AF cut-off at baseline was defined in the discovery cohort with droplet digital PCR (ddPCR). All patients had tissue-confirmed BRAF-V600E mutations. RESULTS: Patients with high AF have major frequency of liver metastases and more metastatic sites. In the discovery cohort, median progression-free survival (PFS) and overall survival (OS) were 4.4 and 10.1 months, respectively. Patients with high BRAF AF (≥2%, n = 23) showed worse PFS [hazard ratio (HR) 2.97, 95% confidence interval (CI) 1.55-5.69; P = 0.001] and worse OS (HR 3.28, 95% CI 1.58-6.81; P = 0.001) than low-BRAF AF patients (<2%, n = 24). In the multivariable analysis, BRAF AF levels maintained independent significance. In the validation cohort, high BRAF AF was associated with worse PFS (HR 3.83, 95% CI 1.60-9.17; P = 0.002) and a trend toward worse OS was observed (HR 1.86, 95% CI 0.80-4.34; P = 0.15). An exploratory analysis of predictive value showed that high-BRAF AF patients (n = 35) benefited more from triplet therapy than low-BRAF AF patients (n = 41; PFS and OS interaction tests, P < 0.01). CONCLUSIONS: Plasmatic BRAF AF determined by ddPCR is a reliable surrogate of tumor burden and aggressiveness in BRAF-V600E-mutant mCRC treated with a BRAFi plus an anti-EGFR with or without a MEKi and identifies patients who may benefit from treatment intensification. Our results warrant further validation of plasmatic BRAF AF to refine clinical stratification and guide treatment strategies.


Asunto(s)
Neoplasias del Colon , Neoplasias Colorrectales , Neoplasias del Recto , Humanos , Pronóstico , Proteínas Proto-Oncogénicas B-raf/genética , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/genética , Neoplasias Colorrectales/patología , Alelos , Mutación , Neoplasias del Colon/genética , Neoplasias del Recto/genética
10.
Injury ; 54 Suppl 7: 111040, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38225165

RESUMEN

BACKGROUND: Reverse total shoulder arthroplasty (RTSA) has recently become an option for the treatment of proximal humerus fractures (PHFs) or as a salvage procedure after failure of another treatment. The purpose of this study was to compare primary RTSA with delayed RTSA in the treatment of displaced PHFs. STUDY DESIGN & METHODS: A retrospective cohort study was conducted on patients with PHFs who were treated between May 2013 and December 2021 with primary or delayed RTSA after failure of conservative treatment or osteosynthesis. Clinical data were withdrawn from our local computerized database. Complications, active range of motion, as well as the functional outcome were recorded at the end of the follow-up period. Differences between clinical outcomes were analyzed using a logistic regression analysis. RESULTS: A total of 70 individuals were included in this study (41 primary RTSA and 29 delayed RTSA). The mean of follow-up time was of 112 and 60 months, respectively. There were no differences between groups regarding fracture type according Neer Classification, ASA score or the presence of complications. Q-DASH and Oxford Shoulder scores were significantly better when patients underwent a primary RTSA (49.8 vs 31.4, p = 0.006 and 37.2 vs 27.5, p = 0.004 respectively). In addition, primary RTSA achieved more degrees of flexion and abduction than delayed RTSA (96.8 vs 72.9, p < 0.001 and 94.1 vs 69.3, p < 0.001 respectively). CONCLUSION: Primary RTSA for PHFs achieved better functional outcomes and a wider range of motion when compared with delayed RTSA. However, primary and delayed RTSA have similar complication and reintervention rates. LEVEL OF CLINICAL EVIDENCE: 3.


Asunto(s)
Artroplastía de Reemplazo de Hombro , Fracturas del Húmero , Fracturas del Hombro , Articulación del Hombro , Humanos , Artroplastía de Reemplazo de Hombro/métodos , Articulación del Hombro/cirugía , Estudios Retrospectivos , Resultado del Tratamiento , Reoperación/efectos adversos , Rango del Movimiento Articular , Fracturas del Húmero/cirugía , Húmero/cirugía
11.
Sci Total Environ ; 779: 146237, 2021 Jul 20.
Artículo en Inglés | MEDLINE | ID: mdl-34030251

RESUMEN

The concept of Nature-Based Solutions (NBS) has emerged to foster sustainable development by transversally addressing social, economic, and environmental urban challenges. However, there is still a considerable lack of agreement on the conceptualization of NBS, especially concerning typologies, nomenclature, and performance assessments in terms of ecosystem services (ES) and urban challenges (UC). Therefore, this article consolidates the knowledge from 4 European projects to set a path for a common understanding of NBS and thus, facilitate their mainstreaming. To do so, firstly, we performed elicitation workshops to develop an integrative list of NBS, based on the identification of overlaps among NBS from different projects. The terminologies were formalized via web-based surveys. Secondly, the NBS were clustered, following a conceptual hierarchical classification. Thirdly, we developed an integrative assessment of NBS performance (ES and UC) based on the qualitative evaluations from each project. Afterwards, we run a PCA and calculated the evenness index to explore patterns among NBS. The main conceptual advancement resides in providing a list of 32 NBS and putting forward two novel NBS categories: NBS units (NBSu) that are stand-alone green technologies or green urban spaces, which can be combined with other solutions (nature-based or not); NBS interventions (NBSi) that refer to the act of intervening in existing ecosystems and in NBSu, by applying techniques to support natural processes. The statistical analysis suggests that NBSu are more versatile than NBSi in terms of UC and ES. Moreover, the results of the integrative assessment of NBS performance suggest a greater agreement concerning the role of NBS in addressing environmental UC, cultural and regulating ES than regarding socio-economic UC and supporting and provision ES. Finally, the 'green factor' and the replication of non-intensive practices occurring in nature seem to be key criteria for practitioners to identify a particular solution as an NBS.

12.
Appl Radiat Isot ; 170: 109634, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33578130

RESUMEN

This contribution describes a kinetic model attempting to reproduce the response of the thermoluminescent material LiF:Mg,Cu,P when it is irradiated to absorbed dose values in the kGy range. The modelling is based on the hypothesis of a relationship between the irradiation time (i.e. the absorbed dose) and the density of trapping/recombination centres. X-ray diffraction and thermal X-ray diffraction measurements have been performed to investigate the potential radiation and thermal damage on the structure of the material, including the possibility of partial phases. The proposed kinetic model qualitatively reproduces the observed changes in the TL glow curve for temperatures above the main peak as well as the two observed regions of absorbed dose response: linear and sub-linear.

13.
J Radiol Prot ; 41(1)2021 Feb 26.
Artículo en Inglés | MEDLINE | ID: mdl-33406511

RESUMEN

Working Group (WG) 6 'Computational Dosimetry' of the European Radiation Dosimetry Group promotes good practice in the application of computational methods for radiation dosimetry in radiation protection and the medical use of ionising radiation. Its cross-sectional activities within the association cover a large range of current topics in radiation dosimetry, including more fundamental studies of radiation effects in complex systems. In addition, WG 6 also performs scientific research and development as well as knowledge transfer activities, such as training courses. Monte Carlo techniques, including the use of anthropomorphic and other numerical phantoms based on voxelised geometrical models, play a strong part in the activities pursued in WG 6. However, other aspects and techniques, such as neutron spectra unfolding, have an important role as well. A number of intercomparison exercises have been carried out in the past to provide information on the accuracy with which computational methods are applied and whether best practice is being followed. Within the exercises that are still ongoing, the focus has changed towards assessing the uncertainty that can be achieved with these computational methods. Furthermore, the future strategy of WG 6 also includes an extension of the scope toward experimental benchmark activities and evaluation of cross-sections and algorithms, with the vision of establishing a gold standard for Monte Carlo methods used in medical and radiobiological applications.


Asunto(s)
Protección Radiológica , Radiometría , Estudios Transversales , Método de Montecarlo , Neutrones , Dosis de Radiación
14.
Mech Ageing Dev ; 186: 111199, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31899226

RESUMEN

Centenarians are remarkable not only because of their prolonged life, but also because they compress morbidity until the very last moments of their lives, thus being proposed as a model of successful, extraordinary ageing. From the medical viewpoint, centenarians do not escape the physiological decline or the age-related diseases or syndromes (i.e. frailty), but the rate of such processes is slow enough to be counterbalanced by their increased intrinsic capacity to respond to minor stresses of daily life (i.e. resilience). These new concepts are reviewed in this paper. Allostatic stresses lead to a chronic low-grade inflammation that has led to the proposal of the "inflammaging" theory of ageing and frailty. The biology of centenarians, described in this review, provides us with clues for intervention to promote healthy ageing in the general population. One of the major reasons for this healthy ageing has to do with the genetic signature that is specific for centenarians and certainly different from octogenarians who do not enjoy the extraordinary qualities of centenarians.


Asunto(s)
Envejecimiento Saludable , Longevidad/fisiología , Anciano de 80 o más Años , Epigénesis Genética , Envejecimiento Saludable/fisiología , Envejecimiento Saludable/psicología , Humanos , Psicología
15.
Appl Radiat Isot ; 153: 108843, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31404764

RESUMEN

Deconvolution analysis of the thermoluminiscent (TL) glow curves proved to be a good complementary method to characterize the individual glow peaks by fitting their kinetic parameters. In this work, new software has been developed for the automatic deconvolution of TL glow curves, assuming either discrete or continuous distribution of trapping centres. The guess estimation of the kinetic parameters is done automatically and can be manually modified, thus allowing the use of the software for routine, processing a large number of measurements, as well as for research purposes. The equations, the methods and the results of the first test are described in detail. The software has been developed by integrating Fortran code and Visual Studio tools to create a graphic easy-to-use environment and permits to obtain the fitted values for the parameters according to the considered model.

17.
Prenat Diagn ; 39(5): 379-387, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30767256

RESUMEN

OBJECTIVE: To ensure accurate and appropriate reporting of non-invasive prenatal testing (NIPT) results, the standard of testing should be measured and monitored by participation in external quality assessment (EQA) schemes. The findings from international pilot EQAs for NIPT for the common trisomies are presented. METHODS: In the first pilot, three EQA providers used artificially manufactured reference materials to deliver an EQA for NIPT. The second pilot used clinically collected maternal plasma samples. The testing and reporting for aneuploidy status was performed by participating laboratories using routine procedures. Reports were assessed against peer ratified criteria and EQA scores were returned to participants. RESULTS: Forty laboratories participated in the first. Genotyping accuracy was high; four laboratories reported a critical genotyping error (10%) and two reported partial results. Eighty seven laboratories participated in the second pilot using maternal plasma, two reporting a critical genotyping error (2.3%). For both rounds, report content was variable with key information frequently omitted or difficult to identify within the report. CONCLUSIONS: We have successfully delivered an international pilot EQA for NIPT. When compared with currently available manufactured materials, EQA for NIPT was best performed using clinically collected maternal plasma. Work is required to define and improve the standard of reporting.


Asunto(s)
Pruebas Prenatales no Invasivas/normas , Femenino , Humanos , Internacionalidad , Embarazo , Garantía de la Calidad de Atención de Salud
18.
Lupus ; 28(3): 396-405, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-30760090

RESUMEN

BACKGROUND: Antibodies to M-type phospholipase A2 receptor (a-PLA2R) have been identified in most patients with idiopathic membranous nephropathy, but the prevalence in membranous lupus nephritis (MLN) is still unclear. The objective of this study was to assess the prevalence of a-PLA2R antibodies in a large cohort of patients with lupus nephritis. METHODS: a-PLA2R antibodies were measured by ELISA in serum from patients with systemic lupus erythematosus ( n = 190), of whom 37 had a biopsy-proven MLN. Positive samples were confirmed by commercial ELISA kit, Western blot and immunohistochemistry in renal tissue. RESULTS: A total of 10 from 190 patients (5.3%) with systemic lupus erythematosus had circulating a-PLA2R measured by in-house ELISA assay. The antibodies were detected in 7 patients with MLN (18.9%) and 3 patients with non-renal lupus disease (3.2%). PLA2R staining was detected in the kidney biopsy of 5 of the 7 (71.4%) patients with MLN. a-PLA2R levels were associated with active disease but not proteinuria levels. Presence of a-PLA2R antibodies at baseline was associated with worse remission rates and longer time to remission compared to those patients serologically negative. CONCLUSIONS: a-PLA2R antibodies can be detected with low prevalence in MLN patients, but their detection is associated with a worse renal prognosis.


Asunto(s)
Autoanticuerpos/inmunología , Nefritis Lúpica/inmunología , Receptores de Fosfolipasa A2/inmunología , Adulto , Autoanticuerpos/sangre , Biomarcadores/sangre , Western Blotting , Estudios de Casos y Controles , Progresión de la Enfermedad , Ensayo de Inmunoadsorción Enzimática , Femenino , Glomerulonefritis Membranosa/diagnóstico , Humanos , Riñón/inmunología , Estudios Longitudinales , Nefritis Lúpica/clasificación , Nefritis Lúpica/diagnóstico , Masculino , Valor Predictivo de las Pruebas , Proteinuria , Receptores de Fosfolipasa A2/sangre , Estudios Retrospectivos
19.
Appl Radiat Isot ; 142: 38-41, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30248587

RESUMEN

CSYP (CYlindrical SPectrometer) is a directional neutron spectrometer based on a single moderator embedding multiple thermal neutron detectors. Similarly to Bonner Spheres, CYSP responds from thermal up to GeV neutrons and the spectrum is obtained via few-channel unfolding methods. CYSP has the shape of a polyethylene cylinder with diameter 50 cm and height 65 cm. Owing on a thick collimator and on a specifically designed shielding structure, the internal detectors only respond to neutrons coming from a known direction. Internal thermal neutron detectors are one-cm2 6LiF-covered silicon diodes. Un upgraded version of CYPS was developed to work in low intensity applications, such as cosmic field measurements. It is called CYSP-HS (High-Sensitivity) and is equipped with large area 6LiF-covered silicon diodes (LATND, Large Area Thermal Neutron Detectors). Compared with the former CYSP, the sensitivity increased approximately by an order of magnitude. This paper presents CYSP-HS focusing on the new internal detectors, the response matrix and its verification in a reference field of Am-Be available at the Politecnico di Milano.

20.
J Pediatr Hematol Oncol ; 40(4): 304-305, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29621062

RESUMEN

Radiation is a well-known cause of the development of cataracts. For children with brain tumors, craniospinal irradiation (CSI) would be expected to result in a significant risk of cataract development. We reviewed the incidence of cataracts in children with brain tumors who received CSI at our institution. Of 45 children who received CSI and had ophthalmologic examinations, 13 developed cataracts. The median time to develop cataracts was 27.6 months. Seven children underwent surgery for cataract. Given this high incidence of cataracts, we suggest routine eye examinations for all children receiving CSI.


Asunto(s)
Neoplasias Encefálicas/epidemiología , Neoplasias Encefálicas/radioterapia , Catarata/epidemiología , Irradiación Craneoespinal/efectos adversos , Traumatismos por Radiación/epidemiología , Adolescente , Catarata/etiología , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Traumatismos por Radiación/etiología , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...